Related Experiment Video
Updated: Jan 31, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
pH-sensitive Eudragit® L 100 nanoparticles promote cutaneous penetration and drug release on the skin
Pin Dong1, Fitsum Feleke Sahle2, Silke B Lohan3
1Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Abstract:
Nanoparticles (NPs) are promising carriers for dermal and transdermal drug delivery. However, the underlying dynamics of drug release from the NPs, especially, how the physiological changes of diseased skin influence the drug release, remain poorly understood. We utilized electron paramagnetic resonance (EPR) and confocal laser scanning microscopy (CLSM) to comprehensively investigate the penetration behavior of a spin-labeled dexamethasone (DxPCA)-loaded pH-sensitive Eudragit® L 100 NP on intact and barrier-disrupted skins. The EPR investigation showed that a rapid in vitro DxPCA release from the NPs was triggered above pH 5.9. It also demonstrated that the NPs considerably improved the cutaneous penetration of the model drug in comparison to a commercial cream. Besides, as compared to the intact skin, a faster drug release and a higher drug penetration into the viable skin layers were obtained with barrier-disrupted skin. In accordance, CLSM studies confirmed that the NPs enhanced the penetration of the lipophilic model drug Nile red (NR) across the skin, whose penetration depth into glabrous skin was 160 μm. Moreover, a significant transfollicular penetration of NR from the NPs was observed. In conclusion, the pH-sensitive Eudragit® L 100 NPs improved the cutaneous penetration and controlled the release of a lipophilic drug, especially on barrier-disrupted skin. This may allow targeted drug delivery to lesional skin, avoiding side effects.
More Related Videos
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
In Vitro Drug Release Testing: Overview, Development and Validation
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...

